{
  "main_header": {
    "sid": 10039743,
    "name": "Amanta Healthcar",
    "stock_name": "Amanta Healthcar",
    "full_name": "Amanta Healthcare Ltd",
    "name_url": "stocks-analysis/amanta-healthcar",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "163.10",
    "chg": -3.25,
    "chgp": "-1.95%",
    "dir": -1,
    "prev_price": "166.35",
    "mcapval": "646.00 Cr",
    "mcap": "",
    "scripcode": 544502,
    "symbol": "AMANTA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE084K01015",
    "curr_date": "Aug 10",
    "curr_time": "",
    "bse_nse_vol": "1.14 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 10, 2026",
    "traded_date_str": "2026 08 10",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/amanta-healthcar-10039743-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Are Amanta Healthcare Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-amanta-healthcare-ltd-latest-results-good-or-bad-4001527",
        "imagepath": "",
        "date": "2026-05-20 19:26:00",
        "description": "Amanta Healthcare Ltd's latest financial results for Q4 FY26 reflect a complex operational landscape. The company reported net sales of ₹76.99 crores, marking a sequential increase of 3.36% from the previous quarter and a year-on-year growth of 6.84%. This indicates some positive momentum in revenue generation, potentially suggesting improved market penetration or product portfolio expansion.\n\nHowever, the operational efficiency metrics reveal challenges. The net profit for the quarter rose to ₹5.53 crores, a 19.44% increase from Q3 FY26, driven by lower interest costs and a slight uptick in other income. Despite this, the net profit remains below the previous year's figure, highlighting ongoing profitability concerns. The operating margin contracted to 19.42%, down from 20.62% in the prior quarter, indicating significant cost pressures or pricing challenges that may affect the company's ability to maintain..."
      },
      {
        "title": "Amanta Healthcare Ltd Reports Flat Quarterly Performance Amid Margin Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/amanta-healthcare-ltd-reports-flat-quarterly-performance-amid-margin-pressure-4000008",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AmantaHealthcar_fintrenddot_4000008.png",
        "date": "2026-05-20 08:00:24",
        "description": "Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving record net sales and a strong operating profit to interest ratio, the company’s operating profit margin contracted significantly, prompting a downgrade in its Mojo Grade from Hold to Sell."
      }
    ],
    "total": 15,
    "sid": "10039743",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/amanta-healthcare-10039743"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "08-Aug-2026",
      "details": "Earnings Call Transcript for quarter ended June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Monitoring Agency Report",
      "datetime": "08-Aug-2026",
      "details": "Monitoring Agency Report for the quarter ended June 30 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "07-Aug-2026",
      "details": "Publication of Financial Results in Newspapers",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Are Amanta Healthcare Ltd latest results good or bad?

2026-05-20 19:26:00

Amanta Healthcare Ltd's latest financial results for Q4 FY26 reflect a complex operational landscape. The company reported net sales of ₹76.99 crores, marking a sequential increase of 3.36% from the previous quarter and a year-on-year growth of 6.84%. This indicates some positive momentum in revenue generation, potentially suggesting improved market penetration or product portfolio expansion. However, the operational efficiency metrics reveal challenges. The net profit for the quarter rose to ₹5.53 crores, a 19.44% increase from Q3 FY26, driven by lower interest costs and a slight uptick in other income. Despite this, the net profit remains below the previous year's figure, highlighting ongoing profitability concerns. The operating margin contracted to 19.42%, down from 20.62% in the prior quarter, indicating significant cost pressures or pricing challenges that may affect the company's ability to maintain...

Read More

Amanta Healthcare Ltd Reports Flat Quarterly Performance Amid Margin Pressure

2026-05-20 08:00:24

Amanta Healthcare Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving record net sales and a strong operating profit to interest ratio, the company’s operating profit margin contracted significantly, prompting a downgrade in its Mojo Grade from Hold to Sell.

Read More

View All News